南新制药(688189) - 2024 Q3 - 季度财报

Revenue and Profitability - Revenue for Q3 2024 was CNY 35,783,445.19, a decrease of 25.93% year-over-year, and year-to-date revenue was CNY 226,570,852.23, down 59.69% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was a loss of CNY 67,388,600.15, and year-to-date net profit was a loss of CNY 71,836,060.02, reflecting an increase in losses of 11,142.92% year-over-year[2] - Basic and diluted earnings per share for Q3 2024 were both -0.2457, reflecting a significant decline compared to the previous year[2] - Total operating revenue for the first three quarters of 2024 was ¥226,570,852.23, a decrease of 59.7% compared to ¥562,058,852.86 in the same period of 2023[14] - Net loss for the first three quarters of 2024 was ¥82,672,022.37, compared to a net profit of ¥998,459.62 in the same period of 2023, indicating a substantial decline in profitability[16] - The company's basic and diluted earnings per share for the first three quarters of 2024 were both -¥0.2623, compared to ¥0.0024 in 2023, highlighting a negative shift in earnings performance[17] Research and Development - R&D investment totaled CNY 25,419,547.01 in Q3 2024, an increase of 49.13% year-over-year, and accounted for 71.04% of revenue, up 35.75 percentage points[3] - R&D investment for the inhalation solution project increased significantly during the quarter, impacting overall R&D spending[7] - Research and development expenses for the first three quarters of 2024 were ¥26,325,369.38, down 58.8% from ¥63,925,857.68 in the same period of 2023, indicating a reduction in investment in innovation[15] Assets and Liabilities - Total assets as of the end of Q3 2024 were CNY 1,368,560,964.71, a decrease of 21.24% from the previous year[3] - Total current assets decreased from 1,290,011,027.37 RMB to 911,150,884.10 RMB, a decline of approximately 29.3%[11] - Total assets decreased from 1,737,536,466.45 RMB to 1,368,560,964.71 RMB, a decline of approximately 21.2%[12] - The total liabilities of the company as of the reporting date were ¥158,904,683.58, a decrease from ¥435,210,026.70 in the previous year, indicating improved financial stability[16] - Total current liabilities decreased from 429,441,961.38 RMB to 153,760,240.79 RMB, a decline of approximately 64.2%[12] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY 30,109,281.80, down 66.01% compared to the previous year[3] - The net cash flow from operating activities for the first three quarters of 2024 is ¥30,109,281.80, a decrease of 66.0% compared to ¥88,584,510.48 in the same period of 2023[18] - Total cash inflow from operating activities decreased to ¥270,074,284.83, down 56.9% from ¥626,379,760.43 year-on-year[18] - Cash outflow from operating activities also decreased to ¥239,965,003.03, a reduction of 55.5% compared to ¥537,795,249.95 in the previous year[18] - The net cash flow from investing activities for the first three quarters of 2024 is ¥66,336,194.76, compared to a negative cash flow of -¥8,277,653.84 in the same period of 2023[19] - The net cash flow from financing activities for the first three quarters of 2024 is -¥269,668,199.85, an improvement from -¥291,887,142.58 in the same period of 2023[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 9,069[9] - Hunan Pharmaceutical Development Investment Group Co., Ltd. holds 78,400,000 shares, accounting for 28.57% of total shares[10] - Guangzhou Qianyuan Investment Management Enterprise (Limited Partnership) holds 43,120,000 shares, accounting for 15.71% of total shares[10] Other Financial Metrics - The weighted average return on equity was -5.3007% for Q3 2024, a decrease of 3.21 percentage points year-over-year[3] - Non-recurring gains and losses for the year-to-date period amounted to CNY 16,774.42, with a total of CNY 517,510.33 for the year[5] - The company adjusted the prices of some core products to maintain market share, contributing to the decline in revenue[6] - Sales expenses decreased significantly to ¥63,868,011.29 in 2024 from ¥341,793,551.23 in 2023, reflecting a strategic shift in marketing expenditures[15] - The company reported a significant increase in credit impairment losses, amounting to -¥89,365,221.19 in 2024 compared to -¥41,990,781.12 in 2023, indicating rising credit risk[15] - Deferred income tax liabilities increased to ¥1,373,942.26 from ¥1,531,728.57, suggesting potential future tax obligations[16] - The ending balance of cash and cash equivalents as of the end of the third quarter of 2024 is ¥388,506,660.17, down from ¥501,891,678.69 at the end of the same period in 2023[19] - The company received ¥12,103,123.17 from other operating activities, a decrease from ¥17,234,332.14 in the previous year[18] - The company paid ¥40,924,775.62 in taxes, a decrease of 55.7% compared to ¥92,505,208.72 in the same period of 2023[18]